Dermatology Education Foundation DERM NP/PA CME Conference

In this summary of coverage at the DERM 2025 conference, a list of notable stories highlighting acne management strategies is highlighted.

News coverage from DERM 2025 in the field of psoriasis is highlighted in this post-conference summary.

This list highlights a variety of notable DERM 2025 conference news coverage, specifically in the field of atopic dermatitis.

The PAISLEY CLE trial findings highlight deucravacitinib’s efficacy among patients with cutaneous lupus, including those with concurrent SLE.

In a DERM 2025 conference interview, Hebert highlights takeaways from her team’s findings on roflumilast cream in patients aged 3 months to 2 years with atopic dermatitis.

These data were presented at DERM 2025, highlighting recent findings on the impact of tralokinumab on atopic dermatitis.

In her DERM 2025 conference interview, Martinez-Dulay highlights takeaways from her sessions on atopic dermatitis, prurigo nodularis, and lymphoma.

This interview with Cotter highlights his session on the use of AI tools in the dermatology field.

Swanson speaks in this interview segment about her DERM 2025 session on speaking with parents and their children or teens as a clinician.

In this interview, Swanson highlights her DERM 2025 session ‘Systemic Therapy for the Pediatric Acne Patient’ and its takeaways.

In this interview segment with Chilukuri, he highlights takeaways from his DERM 2025 session titled ‘Advancements in Body Contouring.’

In this interview, Friedman highlights notable points from his DERM 2025 talk on managing patients with tinea.

In a new interview at the DERM2025 Conference, Stein Gold highlighted several topical options for patients with psoriasis outside of topical steroids.

In an ADvocate study subpopulation, new findings suggest lebrikizumab therapy leads to significant disease control and positive itch impacts.

This interview segment highlights additional information on the 16-week risankizumab data from the phase 4 UnlIMMited study.

This interview with Song at DERM2025 highlights recent phase 3 data on risankizumab for genital and scalp psoriasis.